Education
About Us
Working with TipRanks
Follow Us
PolyPid Ltd. (PYPD)
NASDAQ:PYPD
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.88Last Year’s EPS
-1.37Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 12, 2025
|% Change Since: 12.15%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
The earnings call presented positive developments, particularly regarding the SHIELD II trial's DSMB recommendation, successful financing, and partnership efforts, which suggest promising future prospects for D-PLEX100. However, increased expenses and net losses highlight ongoing financial challenges.Company Guidance
During the PolyPid Fourth Quarter 2024 Conference Call, the company provided guidance on several key metrics and milestones. PolyPid is advancing its SHIELD II Phase 3 trial with D-PLEX100, a treatment aimed at preventing surgical site infections in abdominal colorectal surgeries. The trial, which has enrolled over 700 patients and expects to reach the 800-patient enrollment target by next month, is on track to report top-line results in Q2 2025. The company anticipates that, if successful, it will submit a New Drug Application (NDA) leveraging Fast Track and Breakthrough Therapy designations. PolyPid also completed a private placement financing of $14.5 million, extending its cash runway into Q3 2025. The exercise of associated warrants could yield an additional $27 million, potentially providing capital beyond NDA approval. Financially, PolyPid reported a net loss of $8.5 million for Q4 2024, an increase from $6.4 million in Q4 2023, with R&D expenses rising to $7 million for the quarter. The company continues to focus on regulatory preparations, potential partnerships, and exploring the market potential for D-PLEX100, which could address over 12 million surgeries annually in the U.S. alone.DSMB Recommendation for SHIELD II Trial
The independent Data Safety Monitoring Board (DSMB) recommended concluding the SHIELD II Phase 3 trial upon the enrollment of 800 patients, suggesting positive efficacy signals from D-PLEX100 for the prevention of surgical site infections.
Successful Private Placement Financing
PolyPid entered into a securities purchase agreement for a private placement financing led by existing institutional shareholders, raising $14.5 million in gross proceeds, extending the company's cash runway into Q3 2025.
Partnership and Collaboration Efforts
PolyPid is in active discussions with potential partners for the commercialization of D-PLEX100, and announced a research and development collaboration with ImmunoGenesis to enhance treatment for solid tumors using PolyPid's technology.
Expansion Opportunities for D-PLEX100
Potential market for D-PLEX100 in the U.S. includes over 12 million surgeries per year, with opportunities in abdominal, gynecology, and urology procedures.
Financial Position and Prospects
PolyPid had cash and cash equivalents of $15.6 million as of December 31, 2024, and expects cash flow to be sufficient to fund operations into Q3 2025.
---
PYPD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PYPD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 12, 2025 | $2.88 | $2.97 | +3.13% |
| Nov 13, 2024 | $3.50 | $3.40 | -2.86% |
| Aug 14, 2024 | $3.56 | $3.49 | -1.97% |
| May 08, 2024 | $4.86 | $4.31 | -11.32% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does PolyPid Ltd. (PYPD) report earnings?
PolyPid Ltd. (PYPD) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is PolyPid Ltd. (PYPD) earnings time?
PolyPid Ltd. (PYPD) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PYPD EPS forecast?
PYPD EPS forecast for the fiscal quarter 2025 (Q1) is -0.88.
---